Acne Vulgaris Clinical Trial
Official title:
Serum apelin12 in Acne Vulgaris
Acne vulgaris is a common chronic inflammatory disease of the pilosebaceous unit which is
characterized by the formation of non-inflammatory open and closed comedones and inflammatory
papules, pustules, nodules and cysts.
It is a multifactorial disease that affects mostly adolescent population. Acne appears very
early in puberty during the preteen years, often before menarche in girls. Because many
adolescents have acne, it is difficult to predict which individuals are prone to severe
cases.
The pathogenesis of acne is complex, with strong evidence supporting the involvement of
follicular hyperkeratinization, hyperactivity of the sebaceous glands, colonization of
Propionibacterium acnes and yeast, and inflammation. Although the importance of androgens in
the pathophysiology of acne has been supported by both clinical studies and experimental
data, the research evaluating adipokines are very few in patients with acne vulgaris.
Acne lesions may vary in number during the natural course of the disease and multiple
measurements have been developed which is based on clinical examination and photographic
documentation, to measure the clinical severity.
The Grading of acne based on the type of lesions, affected surface area and their severity
that can help in deciding which therapies are needed in each individual. However, no grading
system has been accepted universally. The Global Acne Grading System is a quantitative
scoring system to assess the severity of acne. According to this score acne was graded as
mild, moderate, severe and very severe.
The severity of acne was also graded using the Comprehensive Acne Severity Scale.
Adipokines are proteins that are synthesized and secreted primarily by adipocytes in response
to various stimuli, include interleukin 6 and other small molecular weight bioactive proteins
such as adiponectin, resistin, leptin, serpin E1 [also known as plasminogen activator
inhibitor 1 and endothelial plasminogen activator inhibitor], visfatin (also known as
nicotinamide phosphoribosyltransferase), apelin, chemerin, retinol binding protein 4, and
monocyte chemoattractant protein 1.
Due to their different biological properties and diverse cellular targets adipokines are
involved in a wide array of (patho)physiological processes and are responsible for mediating
the inflammatory effects of the adipose tissue in the local tissue environment as well as to
different organs via circulation. By detecting alterations in their serum levels also in
dermatological diseases such as acne vulgaris and psoriasis, extensive studies have also
started in dermatological research to identify the possible targets and the cutaneous sources
of these proteins.
Apelin is an endogenous ligand of the previously discovered "orphan" receptor named APJ,
isolated from bovine stomach extracts.
It is a product of apelin gene that is located on chromosome Xq25-26.1 and translated as a 77
amino acid prepropeptide. It is processed into several active molecular forms with different
biological activities. Apelin belongs to adipokines group because its m-RNA expression has
been demonstrated in mature adipocytes in rodents and humans.
Apelin peptide expression has been also demonstrated in several tissues and seems to have
different regulatory functions, depending on the expressing tissue, the apelinergic system
distribution over such a variety of tissues has suggested that it might play relevant roles
in human physiology.
Apelin has been reported to have an effect on appetite, drinking behavior, angiogenesis, and
the cardiovascular system. It is regulated by insulin. Apelin might be a novel target for
preventing obesity and obesity-related diseases via enhancement of vascular integrity.
Several active apelin forms exist such as apelin-36, apelin-17, apelin-13, and apelin-12.
Apelin-12 is a 12-amino peptide fragment that has been implicated in reducing blood pressure
via a nitric oxide mechanism, and is involved in feeding mechanisms via stimulation of
cholecystokinin secretion.
It is considered to be one of the most potent isoform of apelin.
The studies evaluating the role of adipokines are very few in patient with acne vulgaris.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 |